Centaurus-Latache Dispute Over Oncoclínicas to Proceed to Arbitration After CVM Ruling
Stories are grouped across languages, rewritten into a fixed editorial format, and linked to original sources.
TL;DR
- CVM unanimously ruled Centaurus must make a public acquisition offer for Oncoclínicas.
- Latache group shareholders advocated for the offer, citing corporate restructuring.
- Centaurus disputes the obligation and has commenced arbitration at the CAM.
- Up to R$6 billion is at stake; the dispute's outcome will be decided through arbitration.
Overview
A unanimous ruling by Brazil's securities regulator (CVM) has reversed a prior technical decision, obliging Centaurus to conduct a statutory public acquisition offer (OPA) for shares in Oncoclínicas, complying with a request from a group of shareholders led by Latache.
Josephina III, a fund linked to Centaurus, opposes the CVM ruling and has commenced arbitration proceedings at the Market Arbitration Chamber (CAM) to contest the obligation, arguing the underlying corporate restructuring does not constitute a new acquisition.
The dispute centers on corporate changes and the applicability of OPA requirements, with up to R$6 billion at stake.
What Happened
On August 25, 2026, the board of the Brazilian Securities Commission (CVM) unanimously ruled that Centaurus must make a statutory public acquisition offer (OPA) for shares of Oncoclínicas.
This decision reversed a prior assessment by the technical department (SRE) of the CVM, which had not found grounds to require the OPA.
The shareholder group led by Latache advocated for the OPA, arguing that recent corporate restructuring involving Centaurus constituted a new acquisition triggering the requirement.
Josephina III, a fund linked to Centaurus, disagreed with CVM and initiated arbitration before the CAM, asserting that the restructuring did not create a new relevant stake but simply transferred an existing investment right. Josephina III claims the dispute should be resolved by the arbitral tribunal according to Oncoclínicas' bylaws.
The arbitration will address whether article 39 of the company's bylaws requires Centaurus to make the OPA after the November 2024 restructuring. The CVM ruling is administrative and not binding on the arbitral tribunal.
The amount in dispute could reach up to R$6 billion, reflecting the value at stake in the potential public offer.
Context
The controversy originates from a November 2024 restructuring, where Centaurus' stake in Oncoclínicas was transferred between affiliated funds.
Prior court decisions involving Latache acknowledged the requirement for disputes under the company's bylaws to be resolved through arbitration.
The CVM ruling is not binding on the arbitral tribunal, leaving it up to arbitrators to determine the necessity of the OPA.
Why It Matters
- The case could clarify the interplay between regulatory (CVM) decisions and arbitration in Brazil's capital markets.
- A substantial amount, up to R$6 billion, is involved, potentially affecting shareholder rights and future corporate actions.
- The outcome may set procedural expectations for how similar disputes between shareholders and controlling entities are handled.